Latest Articles

Publication Date
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive

Managing Progression After Immunotherapy in Endometrial Cancer OncLive

Published: May 5, 2026, 12:07 p.m.
High response rates in platinum-resistant ovarian cancer with immunotherapy agents - MSN

High response rates in platinum-resistant ovarian cancer with immunotherapy agents MSN

Published: April 20, 2026, 8:14 a.m.
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times

Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times

Published: April 17, 2026, 12:30 p.m.
High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents - MedPage Today

High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents MedPage Today

Published: April 16, 2026, 7:11 p.m.
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …

Published: April 10, 2026, midnight
Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.

Endometriosis and endometrial cancer are distinct gynecological conditions that share overlapping biological mechanisms with implications for clinical management. Endometriosis is a chronic, benign disorder characterized by the ectopic implantation of …

Published: April 10, 2026, midnight
CAR-NKT cell therapy offers scalable, off-the-shelf immunotherapy for endometrial carcinoma - Oncology Central

CAR-NKT cell therapy offers scalable, off-the-shelf immunotherapy for endometrial carcinoma Oncology Central

Published: March 23, 2026, 9:45 a.m.
CAR-NKT cell therapy: a scalable immunotherapy option for endometrial carcinoma - Oncology Central

CAR-NKT cell therapy: a scalable immunotherapy option for endometrial carcinoma Oncology Central

Published: March 23, 2026, 9:45 a.m.
CAR-NKT Immunotherapy Eliminates Endometrial Tumors in Preclinical Models - Cure Today

CAR-NKT Immunotherapy Eliminates Endometrial Tumors in Preclinical Models Cure Today

Published: March 17, 2026, 5:11 p.m.
CAR-NKT Immunotherapy Eliminates Endometrial Tumors in Preclinical Models - CUREtoday.com

CAR-NKT Immunotherapy Eliminates Endometrial Tumors in Preclinical Models CUREtoday.com

Published: March 17, 2026, 4:12 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!